Australia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.
View noteClinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.
View noteHarvey Norman trades at $7.29 vs $3.13 fair value (57% overvalued) with unsustainable margins and property cycle risks creating compelling value opportunity
View noteTrading at $1.00 vs fair value $0.88. Business quality 5.9/10, EBITDA margins compressing 49.9% to 44.7%. Development pipeline finite, competitive moat narrowing 4-6 years.
View noteHOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.
View noteHOLD rating with $1.47 fair value vs $1.757 current price. Exceptional 76% EBITDA margins offset by defensive positioning headwinds and succession risk.
View noteHOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.
View noteTrading at $35.89 vs fair value $18.38 (95% premium). Development margins at 47.8% face compression to 42%. ROIC 8.2% trails WACC 9.6%. Quality business, extreme valuation.
View noteGenesis Minerals trades at A$4.53 versus fair value A$1.75 (-61%), with 49.4% EBITDA margins facing compression to 39% as grade depletes from 2.7g/t to 2.0g/t. ROIC 21.8%, narrow moat (6-8 years), high execution risk on A$1.5bn expansion.
View noteFSA Group analysis reveals negative $4.84 fair value despite operational improvements, with 15% probability of positive equity value given structural debt overhang.
View noteFletcher Building trades at $2.84 vs fair value $5.56, offering 96% upside through construction cycle recovery and strategic portfolio optimization.
View noteNova Eye Medical: BUY rating, A$0.48 fair value vs A$0.14 current price (243% upside). Pre-profit MIGS specialist targeting H1FY26 breakeven with 25% revenue growth.
View note